GC–MS/MS analysis of syntheticcannabinoids 5F-MDMB-PICA and5F-CUMYL-PICA in forensic cases: supplementary materials

Aim: Validate a method to quantify 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
(5F-CUMYL-PICA) and methyl 2-[[1-(5-fluoropentyl) indole-3-carbonyl] amino]-3,3-dimethyl-butanoate
(5F-MDMB-PICA) in blood samples using GC–MS/MS. Materials & methods: A solid-phase extraction (SPE)
method has been developed to quantify 5F-MDMB-PICA and 5F-CUMYL-PICA in authentic human blood
samples. Results & conclusion: The limit of detection (LOD) was 0.1 and 0.11 ng/ml for 5F-CUMYL-PICA
and 5F-MDMB-PICA, respectively, while the limit of quantification (LOQ) was 0.50 ng/ml for both two
compounds. Recovery was 91.40, 82.54 and 85.10% for SPE, supported liquid extraction (SLE) and ISOLUTE
C18; matrix effects 15, 24 and 22.5% for SPE, SLE and ISOLUTE C18; accuracy was 2.4-5.5 and 3.9-7.3%
for SPE, SLE and ISOLUTE C18, while precision was 4.6-7.7 and 6.4-8.3% for SPE, SLE and ISOLUTE C18,
respectively. The concentrations of 5F-CUMYL-PICA and 5F-MDMB-PICA in the authentic human blood
samples were 2.18 and 3.07 ng/ml, respectively. The validated method was successfully used in supporting
the quantification of analytes in blood.